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Recent studies of the involvement of the bone marrow in
human atopic asthmatic responses to inhaled allergen
confirm what we have found in a canine model of Ascaris
suum-induced bronchial hyperresponsiveness. CD34/45þ
hemopoietic progenitors, increased in numbers in the blood
and marrow of atopic individuals, can be specifically
upregulated following airway allergen challenge eliciting
bronchial hyperresponsiveness and the late-phase response.
All the IL-5 responsive subset of progenitors, making the
Eo-B lineage specifically, is unregulated in the marrow
within 24 h of allergen challenge in dual responder
asthmatics. Using triple colour flow cytometry, it can be
shown that this subpopulation of progenitors in the
marrow is one that bears high anity receptors for IL-5
(IL-5Ra), existing as a subpopulation of early progenitors
bearing CD34/45 (1,2). Thus, the readily mobilizable pool
of autocrine [GM-CSF- and IL-5-producing (3)] Eo-B
progenitors at a very early stage of lineage commitment is
increased after inhalation of allergen, only in those
individuals who develop ongoing inflammatory responses.
The nature of the signalling between the airway and the
bone marrow, which upregulates IL-5Ra on CD34þ
progenitors in the bone marrow in vivo, is not yet known.
We therefore undertook studies to explore the in vitro
regulation of IL-5R expression on hemopoietic progenitors.
Effects of retinoic acid
IL-5 plays a central role in eosinophil and basophil
differentiation, exerting its effects through the IL-5 recep-
tor. Though the a chain of the IL-5R is known to exist as
either a membrane-bound or soluble isoform, little is
currently known concerning regulation of IL-5Ra gene
transcription in the context of commitment of haemopoietic
progenitor cells to the eosinophil and basophil lineages.
Recent studies by Tavernier et al. have indicated that IL-
5 itself can regulate IL-5Ra expression on cord blood-
derived mature eosinophils; recent studies in our laboratoryindicate that the same holds for bone marrow eosinophil
progenitors. Given that all-trans retionic acid (ATRA) is
known to modulate some aspects of haemopoietic differ-
entiation, we examined the effects of ATRA on eosinophil/
basophil differentiation and IL-5Ra expression. In semi-
solid cultures of normal human bone marrow, ATRA
selectivity suppressed eosinophil/basophil colony forming
units, but had no effect on granulocyte–macrophage colony
forming units. Similarly, ATRA inhibited eosinophil/
basophil differentiation of cord blood CD34þ cells, while
neutrophil differentiation proceeded without impediment.
Most importantly, these effects of ATRA or CD34þ cells
were associated with selective, dose dependent inhibition of
membrane-bound IL-5Ra, upregulation of soluble IL-5Ra
transcription, but no change in GM-CSF receptor expres-
sion. These findings indicate that retinoids can differentially
regulate membrane and soluble isoforms of IL-5Ra, and
that these effects have functional consequences in vitro on
eosinophil and basophil differentiation.
Cord blood studies: prediction of
atopy?
The above findings point to an association between allergic
asthma and increased responsiveness of myeloid progenitor
cells to certain haemopoietic growth factors. However, it is
not clear at what age these changes in progenitor cells first
becomes manifest, though increasing evidence suggests that
the allergic phenotype may begin to emerge in very early
life. We therefore compared expression of haemopoietic
cytokine receptors on CD34þ progenitor cells in cord blood
from normal infants (at ‘low risk’ for subsequent atopy),
and infants with at least one atopic first degree relative (‘at
risk’ for subsequent atopy), by flow cytometry. Although
no differences in absolute CD34þ numbers were observed
between the two groups, expression of GM-CSF receptor
on CD34þ cells was significantly reduced in the ‘at risk’
compared to the ‘low risk’ group (P¼0?021), with a
tendency to reduced IL-3 and IL-5 receptor expression in
the ‘at risk’ group (4). While the functional sequelae of
reduced GM-CSF receptor expression on CD34þ cells
remain to be determined, these findings show an association
between genetic risk for atopy and changes in the
expression of haemopoietic cytokine receptors on cord
blood progenitor cells.
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upregulate IL-5Ra expression
The receptor for interleukin 5 receptor consists of a
cytokine-specific a chain (IL-5Ra), and a signalling b chain,
which is shared with IL-3 and GM-CSF (1,2). These three
cytokines can act in eosinophil development and activation
in vitro, but gene deletion or antibody blocking of IL-5
largely ablates eosinophilic responses in models of allergic
disease or helminth infection. Differential IL-5Ra gene
splicing generates either the membrane-anchored isoform
(TM-IL-5Ra), which associates with the common b chain
to allow IL-5 responsiveness, or a secreted, antagonist
variant (SOL-IL-5Ra) (3). To examine the expression of IL-
5Ra isoforms during human eosinophil development a
system of in vitro eosinophil development from umbilical
cord blood CD34+ progenitor cells grown in IL-3 and IL-5
was used. These cells developed towards the eosinophil
lineage with 84?5%, (range 75–88%, n=10) expressing
major basic protein and showing characteristic eosinophilic
granules by day 14. Competitive RT-PCR showed upregu-
lation of IL-5Ra-TM mRNA relative to that of the soluble
isoform at day 5–7 of culture in IL-3+IL-5. IL-5Ra
expression at the cell surface also increased over time in
culture and a maximal chemokinetic response to IL-5 was
seen by day 7 of culture in IL-3+IL-5. This upregulation ofTM-IL-5Ra was also seen in eosinophils developing in IL-3
or IL-3 and GM-CSF without exogenous IL-5. However,
the switch to TM-IL-5Ra appeared to be IL-5 dependent,
since eosinophil development was blocked by inclusion of
anti-IL-5 (antibody 5A5) in cultures, and IL-5 mRNA was
demonstrated at day 3–5 before TM-IL-5Ra upregulation.
Similar switching from SOL-IL-5Ra to TM-IL-5Ra was
shown in a mingene system in transfected cell lines, and
such switching was seen in response to IL-5, but not IL-3 or
GM-CSF.
These findings suggest that eosinophil development and
lineage expansion is IL-5 dependent, in keeping with the
pronounced eosinophilia seen in IL-5 transgenic mice (4),
and raise the possibility of IL-5 specific signalling (not
shared by IL-3 and GM-CSF, which with IL-5 have a
common receptor b subunit).
Interleukin-9 increases eosinophil
expansion through upregulation of
IL-5Ra
IL-9 has been linked by genetic studies to bronchial
hyperresponsiveness (BHR) in mice and humans, and
transgenic targeting of IL-9 to the airway epithelium in
mice leads to eosinophil infiltration, mast cell hyperplasia
and BHR (5,6). Addition of IL-9 to human umbilical cord
blood CD34+ cells cultured in IL-3 and IL-5 increased cell
yields at day 7 and day 14 in a dose dependent manner,
(mean increase in cell number at day 7, 17%, range 11–
23%, n=5, and 35% at day 14, range 13–57%, n=5). In
addition, flow cytometry showed that addition of IL-9 to
CD34+ progenitors grown in IL-3 and IL-5 increased
expression of IL-5Ra at day 7 and 14, mean increase in
fluorescence for IL-9 added to IL-3+IL-5 at day 7, 47%
n=3, and 80?4% at day 14 n=3. RT-PCR showed that
mRNA for both soluble and membrane associated IL-5Ra
isoforms was induced at days 7 and 14 of culture in IL-9
alone. In addition, IL-9 increased IL-5Ra expression by
mature eosinophils and HL-60 cells developing towards the
eosinophil lineage (not shown). These data suggest that one
mechanism by which IL-9 may contribute to BHR is by
increased IL-5 responsiveness of developing and mature
eosinophils.
CD34+/IL-5Ra mRNA+ cells can be
detected in the airway in asthma
CD34+/IL-5Ra mRNA+ cell numbers detected by simul-
taneous immunohistochemistry for CD34 and in situ
hybridization were increased in bronchial biopsies from
asthmatic subjects when compared to atopic non-asth-
matics and non-atopic control subjects (7). Amongst the
asthmatic subjects there was a significant correlation
between eosinophil numbers and numbers of IL-5Ra
mRNA+ cells in bronchial biopsies (rs ¼ 0  90; P < 0  001)
and between FEV1 and Cd34
+/IL-5Ra mRNA+ cell
numbers for asthmatic subjects (rs ¼ ÿ0  72;P < 0  02)
